News
Danaher Corporation has announced a collaboration with AstraZeneca for diagnostic tools and tests development and ...
New research has shown that the ArteraAI test can help identify which men with non-metastatic high-risk prostate cancer are ...
Acclaro Medical has completed a Series B funding round, raising $23m, to spur the growth of its flagship products, UltraClear ...
Moximed has announced the treatment of the first subject in the MOTION randomised controlled trial (RCT) assessing its MISHA ...
HistoSonics' Edison histotripsy system has been granted controlled early limited market access in the UK under an Unmet ...
Helix has released a new suite of pharmacogenomics (PGx) tests, widening its portfolio in neurology and oncology.
The FDA has granted 510(k) clearance for Distalmotion’s DEXTER robotic surgery system to be used in adult cholecystectomies.
The US structural heart occlusion (SHO) market recorded a strong 39% year-over-year revenue increase in the first quarter (Q1 ...
BD is set to commence a multi-centre registry study, XTRACT, of the Rotarex Atherectomy System, for peripheral artery disease ...
NeuroPace has reported the initial primary endpoint one-year outcomes from the NAUTILUS trial of the RNS System.
Danish medtech Brainreader has secured $7.3m (€6.6m) to support the market rollout of Neuroreader, its artificial ...
SAGA Diagnostics has commercially launched the multi-cancer molecular residual disease (MRD) platform, Pathlight, in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results